H.C. Wainwright raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $125 from $120 and keeps a Buy rating on the shares. The firm says management commentary strengthens its conviction in its above- guidance Tryngolza peak estimates.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals price target raised to $115 from $106 at Barclays
- Ionis Pharmaceuticals’ Earnings Call Flags Growth and Risks
- Analyst Reiterates Buy Rating on Ionis Pharmaceuticals, Maintains $105 Price Target on Strong Q1 and Upgraded Olezarsen Outlook
- Ionis Pharmaceuticals reports Q1 EPS (56c), consensus (77c)
- Ionis Pharmaceuticals raises FY26 revenue view $875M-$900M from $800M-$825M